RNF31 inhibitor(Flindr Therapeutics)

N/A

Report date: 2024/05/11 18:37:35
NMEFirst In Class

Base Information

Drug NameRNF31 inhibitor(Flindr Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionE3 ubiquitin-protein ligase RNF31 inhibitors
TargetsE3 ubiquitin-protein ligase RNF31
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFlindr Therapeutics BV
China Registration ClassN/A

Develop Information

Active CompaniesFlindr Therapeutics BV
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A